Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab Authors: Christina Darwish, Don A Baldwin, Peter Abdelmessieh Published: 2026 ABSTRACT AbstractCD19 directed immunotherapy with monoclonal antibodies and chimeric antigen receptor T (CAR-T) cell therapy has shown treatment efficacy in the relapsed/refractory setting for non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the CD19 directed bispecific T-cell engager, blinatumomab, is currently only approved in B-cell acute lymphoblastic leukemia (ALL) and has largely not been investigated in other clinical contexts for CLL. We report a case of a patient who presented with both Philadelphia chromosome positive (pH+) ALL and CLL who achieved measurable residual disease (MRD) negative remission for both diseases with blinatumomab.Keywords: B-ALL, CLL, blinatumomab, Immunotherapy Introduction Blinatumomab is a bispecific T-cell engager with anti-CD3 and anti-CD19 arms which has shown efficacy in multiple treatment settings for B-cell acute lymphoblastic leukemia (ALL) including induction for Philadelphia chromosome (pH+) ALL as well as consolidation, measurable residual disease (MRD) positivity, and relapsed/refractory disease for both pH- and pH+ ALL [1]. In pH+ ALL, blinatumomab in combination with a tyrosine kinase inhibitor (TKI) can now be considered for induction therapy without chemotherapy [2]. Due to blinatumomab’s success in improving disease responses and prolonging survival in B-ALL, it has also been investigated in other B-cell malignancies including relapsed/refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [[3], [4], [5]]. In two prior phase 2 studies, blinatumomab showed some efficacy in inducing remission for Richter’s transformation though response rates were mostly incomplete or were not durable [4,5]. In this report, we discuss a case in which blinatumomab consolidation for the treatment of pH+ B-ALL led to eradication of a concomitant CLL clone. Though the presence of pH+ B-ALL obfuscated whether the patient's CLL would otherwise have required treatment, repeat bone marrow biopsy after cycle 3 of consolidation showed MRD negativity in both of this patient's ALL and CLL clones. Case presentation A 75-year-old man initially presented with diminished appetite, unintentional weight loss, fatigue, and fever in April 2024. Documented physical examination did not note lymphadenopathy or hepatosplenomegaly. However, initial staging imaging with computed tomography of the chest/abdomen/pelvis demonstrated mild splenomegaly measuring 15 cm in length and “shotty” mediastinal lymphadenopathy. Complete blood count was notable for leukocytosis with a white blood cell count of 14.3 K/mm3 with 39% blasts, an absolute lymphocyte count of 7.6 K/mm3, an absolute neutrophil count of 0.9 K/mm3, a hemoglobin of 10.9 g/dl, and platelets of 12 K/mm3. Smear examination demonstrated numerous circulating blasts intermediate to large in size with irregular nuclear contours, open chromatin, inconspicuous nucleoli, and scant cytoplasm, and small mature lymphoid cells with condensed chromatin consistent with a CLL-type morphology. Peripheral flow cytometry showed a 34% lymphocyte population including both a B-lymphoblastic leukemia with 47% blasts as well as a monoclonal CD5+/CD23+ B-cell population representing 66% of lymphocytes (22% of total) consistent with concomitant CLL. Cytogenetic analysis showed a 9;22 translocation in 18/20 metaphases. Cytogenomic microarray analysis demonstrated loss of chromosome segment 7p12.2p12.1 encompassing the IKZF1 gene in ∼70% of the cells and trisomy 12 in ∼20% of the cells. Next generation sequencing demonstrated tier 2 DNA variants of potential clinical significance in KRAS, IKZF1, and KMT2D (Table 1). Two tier 3 variants in EP300 (predicted oncogenic in COSMIC) and NTRK1 (uncertain significance) were identified though both were also present in germline DNA. No concomitant mutation in PAX5, CDKN2A, or CDKN2B was identified in combination with the IKZF1 deletion to suggest IZKF1plus disease. Initial cerebrospinal fluid evaluation did not show evidence of a B-cell clonal population or abnormal B-lymphoblasts. Table 1DNA variants detected by next-generation sequencing.Table 1: dummy alt textGeneProtein ChangecDNA ChangeVAF (PB)VAF (G)TierReference TranscriptEP300p.Met609Ilec.1527G>C50.8%52.2%3ENST00000263253IKZF1p.Arg143Trpc.427C>T37.8%ND2ENST00000331340KMT2Dp.Asp4030fsc.12089_12102delACCCAGCCGTTTCT22.8%ND2ENST00000301067KRASp.Gly12Aspc.35G>A4.6%ND2ENST00000311936NTRK1p.Ile228Valc.682A>G48.6%49.7%3ENST00000524377VAF: variant allele frequency, PB: peripheral blood, G: germline DNA from fingernails, ND: not detected. DNA variants detected by next-generation sequencing. VAF: variant allele frequency, PB: peripheral blood, G: germline DNA from fingernails, ND: not detected. ECOG performance status was assessed as 1. He was initially treated with induction for ALL with vincristine, dexamethasone, and dasatinib. He did not receive vincristine on day 15 and dexamethasone on days 15–16 due to neutropenic fever. Vincristine was dose reduced from 2 mg to 1 mg on days 8 and 22 due to age. Post induction bone marrow biopsy was obtained on day 39. This showed a hypercellular marrow (70%) with trilineage hematopoiesis and corresponding peripheral blood counts were consistent with complete remission. However, focal lymphoid infiltrates (∼15% cellularity) were demonstrated and flow cytometry of the bone marrow aspirate detected a monoclonal CD5+/CD23+ B-cell population consistent with known CLL and was otherwise negative for lymphoblasts. BCR-ABL was not detected. Chromosomal microarray demonstrated trisomy 12 in 30% of cells. Measurable residual disease (MRD) was positive with 120,798 of one million nucleated cells in 3 of the 6 dominant sequences identified, all presumably related to the CLL clone. He was subsequently transitioned to blinatumomab consolidation with continuation of dasatinib for consolidation as per the GIMEMA LAL2116 trial [2]. Dasatinib was briefly changed to ponatinib during the first cycle of blinatumomab due to concern for underlying IKZF1 deletion and its association with tyrosine kinase inhibitor resistance [6]. However, he subsequently developed a rash which was attributed to ponatinib and was transitioned to asciminib. After cycle 3 of blinatumomab and asciminib, he underwent repeat bone marrow biopsy which showed no morphologic or immunophenotypic evidence of residual acute leukemia or persistent CLL clone. BCR-ABL was not detected. MRD was negative for both ALL and CLL clones. He received four total cycles of blinatumomab and 15 total cycles of intrathecal chemotherapy alternating between cytarabine and methotrexate for central nervous system prophylaxis. He has had no evidence of a monoclonal B cell population on flow cytometry of cerebrospinal fluid throughout treatment. He has remained on TKI therapy with either ponatinib or asciminib since. MRD testing has continued to remain negative in the peripheral blood as of September 2025 (Table 2). Table 2Measurable residual disease by next generation sequencing.Table 2: dummy alt textBiomarker% clonal cellsPBDxBM2 monthsBM5 monthsPB15 monthsPB17 monthsIGH sequence A23.612.1NDNDNDIGH sequence B29.6NDNDNDNDIGH sequence C26.6NDNDNDNDIGH sequence D23.710.6NDNDNDIGH sequence E23.8NDNDNDNDIGK sequence F23.812.1NDNDNDPB: peripheral blood, Dx: diagnosis, BM: bone marrow, ND: not detected; at Dx: 47% B-ALL 22% CLL; 2 months: 8% CLL; 5, 15, and 17 months: no evidence of disease. Measurable residual disease by next generation sequencing. PB: peripheral blood, Dx: diagnosis, BM: bone marrow, ND: not detected; at Dx: 47% B-ALL 22% CLL; 2 months: 8% CLL; 5, 15, and 17 months: no evidence of disease. Discussion In this report, we present a case of a patient who was simultaneously treated for ALL and CLL with the use of blinatumomab in consolidation for MRD positive pH+ ALL after induction with chemotherapy and a TKI. Though blinatumomab is now widely utilized for the treatment of ALL, its use and investigation in CLL and lymphoma has been limited. It was initially investigated in a phase 1 dose escalation trial for its role in non-Hodgkin’s lymphoma [7]. Among 35 patients treated at the maximum tolerated dose of 60 μg/m2/day, the overall response rate (ORR) was 69% for all subtypes of NHL and 55% for DLBCL specifically, with a median duration of response of 404 days [7]. This trial thus established the anti-lymphoma activity of blinatumomab. However, the development of anti-CD20/anti-CD3 bispecific T-cell engagers, the use of anti-CD20 antibody-drug conjugates, and the advent of CD19 directed CAR-T cell therapy has largely supplanted the investigation of blinatumomab for NHL. There has been limited investigation into the potential utility of blinatumomab in CLL, and it has only been investigated clinically in the setting of Richter’s transformation. A single center phase 2 study evaluated the use of high dose blinatumomab (maximum 112 mg/day) given for an 8-week induction and 4-week consolidation in nine patients who had a median of four and two prior therapies for CLL and Richter’s, respectively [4]. Overall response only occurred in two of nine patients. However, three of five patients with >10% CLL involvement in the bone marrow prior to treatment had reduction in CLL involvement to <0.1% at response assessment [4]. Another multi-center phase 2 trial investigated the use of blinatumomab after R-CHOP in 39 patients with previously untreated Richter’s transformation with DLBCL histology. Blinatumomab was administered as an 8-week induction with stepwise dosing until 112 mg/day. However, only 25/39 patients were ultimately able to receive blinatumomab after R-CHOP. The ORR rate was 46% (18/39 patients) with a complete response rate of 36% (14/39 patients) at a median follow up time of 23.2 months [5]. For the majority of patients, CLL remains a largely indolent disease. However, risk of disease progression and transformation can vary widely based on independent molecular and cytogenetic features. For those patients who require treatment, front-line therapy with a second generation BTK inhibitor, a combination of venetoclax plus an anti-CD20 monoclonal antibody, or a combination of a BCL2 inhibitor and a BTK inhibitor often leads to durable and sustained remissions [8]. In the relapsed/refractory setting, CD19 directed immunotherapy with chimeric antigen receptor T (CAR-T) cell therapy, lisocabtagene maraleucel (lisocel), has demonstrated efficacy in both achieving response and MRD negativity in a subset, though minority, of patients [9]. Though not widely utilized in clinical practice, MRD status in CLL has also been demonstrated to be an independent prognostic factor of survival, and current upfront therapies for CLL vary in their efficacy in inducing an MRD negative remission [10]. Notably, the efficacy of T cell directing therapies in CLL may be affected by associated T cell dysfunction resulting from numerous mechanisms including chronic antigen stimulation and T cell receptor repertoire restriction, increase in the T cell exhaustion phenotype, induced cytoskeletal defects resulting in impaired immune synapse formation, and expansion of regulatory T cell subpopulations [11]. The use of additional agents, such as checkpoint inhibitors, to promote T cell effector function in combination with treatment with blinatumomab is currently under investigation [12]. Continuation of use of other CLL directed therapies including BTK inhibitors and BCL2 inhibitors in combination with blinatumomab could also be considered. In this report, we describe a novel case in which a patient was simultaneously diagnosed with pH+ ALL and CLL. After treatment with induction chemotherapy and a TKI, the CLL clone was still detected on follow up with bone marrow biopsy. However, subsequent treatment with 3 cycles of blinatumomab led to eradication and MRD negativity of both ALL and CLL. Though blinatumomab has had limited investigation in clinical settings outside of ALL, this report demonstrates that if administered prior to progression or transformation of disease, there is a possibility of achieving MRD negative remission with CD19 directed immunotherapy. Currently, the decision for treatment of CLL is only based on the presence of clinical features. However, there is increasing information to suggest the prognostic importance of underlying molecular features in treatment planning. It is possible that a subset of patients with high-risk disease may benefit from earlier consideration of treatment. For those patients, a treatment approach with the goal of MRD negativity may lead to improved long term survival outcomes. CRediT authorship contribution statement Christina Darwish: Writing – review & editing, Writing – original draft, Investigation. Don A. Baldwin: Writing – review & editing, Investigation, Formal analysis, Data curation. Peter Abdelmessieh: Writing – review & editing, Supervision, Investigation, Funding acquisition, Formal analysis, Conceptualization. Declaration of competing interest Christina Darwish, MD and Donald Baldwin, PhD have no disclosures to declare. Peter Abdelmessieh, DO is a speaker for Amgen and serves on the advisory board for Cogent Biosciences. References